Lancet correction reveals systemic gaps in Down syndrome epilepsy research: prevalence errors and affiliation oversights mask structural inequities in neurodevelopmental healthcare
Original framing: “[Department of Error] Department of Error” — The Lancet
Self-advocates from Down Syndrome International (DSi) have repeatedly testified at WHO: 'We are not studied with, we are studied on.' The correction notice — fixing a number and an affiliation — exemplifies research done *on* not *with*. No adult with Down syndrome reviewed the protocol, consent forms, or dissemination plan. The 'multicentre' claim obscures that centres were university hospitals, not community organisations. Marginalised voices would demand: where is the easy-read summary? Where is the data return to families? Where is the advocacy for seizure action plans in supported living?
The Lancet's correction notice — a decimal-point fix and an affiliation update — functions as a trickster's mirror: it reflects the precision of academic self-policing while concealing the folly of a field that has studied Down syndrome epilepsy for four decades without moving the prevalence needle, without including the studied population in the study design, and without building care systems that match the 145.
2/1000 reality. The restored elements — historical stasis, diagnostic overshadowing, Indigenous data sovereignty, Japanese care infrastructure, self-advocate co-production — converge on a single systemic failure: the epistemic apartheid that separates 'research on' from 'care for' adults with Down syndrome. Hermes would note the boundary violation: the correction department corrects the text but not the context. The solution pathways — inclusive design mandates, global registries with OCAP® governance, embedded screening, dedicated therapeutics funding — are not add-ons; they are the structural repairs that the correction notice's existence proves are overdue. The 145.2 per 1000 is not a statistic to correct; it is a covenant to honour.